ClearPoint Neuro (CLPT)
(Delayed Data from NSDQ)
$12.89 USD
+0.50 (4.04%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $12.86 -0.03 (-0.23%) 7:58 PM ET
4-Sell of 5 4
F Value B Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$12.89 USD
+0.50 (4.04%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $12.86 -0.03 (-0.23%) 7:58 PM ET
4-Sell of 5 4
F Value B Growth A Momentum C VGM
Zacks News
Inogen (INGN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of 34.38% and 10.33%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
ClearPoint Neuro, Inc. (CLPT) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
ClearPoint Neuro, Inc. (CLPT) delivered earnings and revenue surprises of 21.05% and 6.61%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Shockwave Medical (SWAV) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Shockwave Medical (SWAV) delivered earnings and revenue surprises of 35.29% and 4.36%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
ClearPoint Neuro, Inc. (CLPT) delivered earnings and revenue surprises of 0% and 0.70%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Hologic (HOLX) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Hologic (HOLX) delivered earnings and revenue surprises of 37.68% and 11.88%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Acadia Healthcare (ACHC) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Acadia Healthcare (ACHC) and ClearPoint Neuro, Inc. (CLPT) have performed compared to their sector so far this year.
ClearPoint Neuro, Inc. (CLPT) Surges 7.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
ClearPoint Neuro, Inc. (CLPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
ClearPoint Neuro, Inc. (CLPT) delivered earnings and revenue surprises of -21.43% and -1.64%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
ClearPoint Neuro, Inc. (CLPT) Stock Jumps 9.8%: Will It Continue to Soar?
by Zacks Equity Research
ClearPoint Neuro, Inc. (CLPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Earnings Preview: ClearPoint Neuro, Inc. (CLPT) Q1 Earnings Expected to Decline
by Zacks Equity Research
ClearPoint Neuro, Inc. (CLPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ClearPoint Neuro, Inc. (CLPT) Surges 12.8%: Is This an Indication of Further Gains?
by Zacks Equity Research
ClearPoint Neuro, Inc. (CLPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
ClearPoint Neuro, Inc. (CLPT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
ClearPoint Neuro, Inc. (CLPT) delivered earnings and revenue surprises of 30.77% and 0.43%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate MRI Interventions, Inc. (CLPT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
MRI Interventions, Inc. (CLPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MRI Interventions, Inc. (CLPT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
MRI Interventions, Inc. (CLPT) delivered earnings and revenue surprises of 31.25% and 32.16%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: MRI Interventions, Inc. (CLPT) Q2 Earnings Expected to Decline
by Zacks Equity Research
MRI Interventions, Inc. (CLPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.